Search
Search Results
-
Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease
Two monoclonal antibodies (mAbs), aducanumab and lecanemab, have received accelerated approval from the US FDA for initiation of treatment in early...
-
Anti-Amyloid Immunotherapies for Alzheimer’s Disease: A 2023 Clinical Update
The amyloid cascade hypothesis is a useful framework for therapeutic development in Alzheimer’s disease (AD). Amyloid b 1-42 (Aβ) has been the main...
-
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
BackgroundThis review describes the research and development process of gantenerumab, a fully human anti-amyloid monoclonal antibody in development...
-
-
Anti-inflammatory clearance of amyloid-β by a chimeric Gas6 fusion protein
Clearing amyloid-β (Aβ) through immunotherapy is one of the most promising therapeutic approaches to Alzheimer’s disease (AD). Although several...
-
Anti-malaria drug artesunate prevents development of amyloid-β pathology in mice by upregulating PICALM at the blood-brain barrier
BackgroundPICALM is one of the most significant susceptibility factors for Alzheimer’s disease (AD). In humans and mice, PICALM is highly expressed...
-
-
Monoclonal Antibodies: From Structure to Therapeutic Application
The exciting field of therapeutic monoclonal antibodies (mAbs) had its origins when Köhler and Milstein presented their murine hybridoma technology...
-
The Amyloid Cascade Hypothesis Has to Deliver, Finally
The Alzheimer’s field has been intensively searching for a therapy, especially in the last 30 years, while the number of affected individuals has...
-
Injection of amyloid-β to lateral ventricle induces gut microbiota dysbiosis in association with inhibition of cholinergic anti-inflammatory pathways in Alzheimer’s disease
BackgroundAlzheimer's disease (AD) is the most common neurodegenerative disease and its pathogenesis is still unclear. There is dysbiosis of gut...
-
Therapeutic Human Monoclonal Antibodies
Since the discovery of obtaining mouse monoclonal antibodies (MAbs) in 1975 by somatic cell hybridization, there have been rapid developments to use...
-
Polymorphic Alpha-Synuclein Oligomers: Characterization and Differential Detection with Novel Corresponding Antibodies
The pathological hallmark of many neurodegenerative diseases is the accumulation of characteristic proteinaceous aggregates. Parkinson’s disease and...
-
Natural IgG antibodies to β amyloid are decreased in patients with Parkinson’s disease
Natural antibodies (nAbs) against aggregation-prone proteins have been found in healthy normal subjects. These proteins likely have a pathogenetic...
-
Therapeutic effects of anti-amyloid β antibody after intravenous injection and efficient nose-to-brain delivery in Alzheimer’s disease mouse model
Antibody drugs that target amyloid β (Aβ) are considered possible treatments for Alzheimer’s disease; however, most have been dropped from clinical...
-
Antibodies as tools in cytokine discovery and usage for diagnosis and therapy of inflammatory diseases
Polyclonal antisera from patients have been at the basis of the description of autoimmune diseases and today monoclonal antibodies are widely used in...
-
Passive immunotherapy for Alzheimer’s disease: challenges & future directions
Passive immunotherapy with specific antibodies targeting Amyloid β (Aβ) peptide or tubulin-associated unit (tau) protein has emerged as a promising...
-
Development of therapeutic antibodies for the treatment of diseases
Since the first monoclonal antibody drug, muromonab-CD3, was approved for marketing in 1986, 165 antibody drugs have been approved or are under...
-
Alzheimer’s Research Gains Momentum and Spreads Out
In the long shadow of Alzheimer’s research into amyloid and tau biology and function, especially in 2002 and the years to follow, many significant...
-
Amyloid-β (Aβ) immunotherapy induced microhemorrhages are associated with activated perivascular macrophages and peripheral monocyte recruitment in Alzheimer’s disease mice
BackgroundAmyloid-related imaging abnormalities (ARIA) have been identified as the most common and serious adverse events resulting from pathological...
